Lv1
30 积分 2026-03-03 加入
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
5个月前
已完结
Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis
6个月前
已完结
Oral PCSK9 Inhibitors: Will They Work?
6个月前
已完结
Emerging oral therapeutic strategies for inhibiting PCSK9
6个月前
已完结
Abstract 12579: CVI-LM001, a First-in-class Novel Oral PCSK9 Modulator, Lowers Plasma Ldl-c and Reduces Circulating PCSK9 in Preclinical Animal Models and in Hyperlipidemic Human Subjects
6个月前
已关闭
A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis
6个月前
已完结
An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia
6个月前
已完结
皖公网安备34019202002308
